Can-Fite Biopharma Ltd (AMEX:CANF) is reporting second quarter financial results on Thursday 27th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, CANF is expected to report 2Q20 loss of $ 0.33 per share from revenue of $ 0.25 million.
For the full year, analysts anticipate top line of $ 0.95 million, while looking forward to loss of $ 1.75 per share bottom line.
Previous Quarter Performance
Can-Fite Biopharma Ltd communicated loss for the first quarter of $ 0.03 per share, from the revenue of $ 0.20 million. Street analysts expected Can-Fite Biopharma Ltd to report loss of $ 0.66 per share on revenue of $ 1.18 million for the first quarter. The bottom line results beat street analysts by $ 0.63 or 95.45 percent, at the same time, top line results fell short of analysts by $ 0.98 million or 83.05 percent.
Stock Performance
Shares of Can-Fite Biopharma Ltd traded up $ 0.09 or 4.00 percent on Wednesday, reaching $ 2.34 with volume of 374.00 thousand shares. Can-Fite Biopharma Ltd has traded high as $ 2.35 and has cracked $ 2.19 on the downward trend
The closing price of $ 2.34, representing a 108.33 % increase from the 52 week low of $ 1.08 and a 54.55 % decrease over the 52 week high of $ 4.95.
The company has a market capital of $ 36.04 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Can-Fite Biopharma Ltd will be hosting a conference call at 4:15 PM eastern time on 27th August 2020, to discuss its 2Q20 financial results with the investment community. The participants may dial, 1-877-423-9813 Toll Free, and the passcode is 13708494 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website public.viavid.com/player/index.php?id=141284
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The companys lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is in Phase II clinical trials for the treatment of liver cancer and non-alcoholic fatty liver diseases, as well as for hepatocellular carcinoma and hepatitis C virus diseases; and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction.
